Werewolf Therapeutics posts Q2 profit on Jazz asset sale
Werewolf Therapeutics posts Q2 profit on Jazz asset sale
Overview
US biopharma firm reported Q2 collaboration revenue of $21 mln on Jazz asset sale
Company posted Q2 net income of $3.7 mln, reversing prior-year loss
Company repaid all debt to K2 HealthVentures and expects cash to fund operations into Q2 2027
Outlook
Company expects to fund operations into the second qtr of 2027
Werewolf expects updates on strategic alternatives and clinical trial data in second half of 2026
Company says timeline and outcome of strategic alternatives process remain uncertain
Result Drivers
ASSET SALE - Q2 results driven by $21 mln collaboration revenue from sale of JZP898 program to Jazz Pharmaceuticals
LOWER R&D SPENDING - Research and development expenses fell to $6.2 mln from $13.1 mln a year ago
Company press release: ID:nGNX6tgRRr
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Collaboration Revenue |
| $21 mln |
|
Q2 Net Income |
| $3.67 mln |
|
Q2 Basic EPS |
| $0.08 |
|
Q2 Operating Expenses |
| $13.84 mln |
|
Q2 Operating Income |
| $7.16 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Werewolf Therapeutics Inc is $7.00, about 1,298.9% above its July 30 closing price of $0.50
Reuters Recommended Reads
July 30 - Anavex Life Sciences Q2 net loss narrows on lower R&D costs
July 30 - Crescent Biopharma posts smaller-than-expected Q2 net loss
July 30 - PTC Therapeutics Q2 revenue more than doubles, raises 2026 outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)